Research programme: cancer therapeutics - Alligator Bioscience

Drug Profile

Research programme: cancer therapeutics - Alligator Bioscience

Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-1015; ADC-CHIPS; ATOR 1015; ATOR 1017; Bispecific antibodies for cancer indications - Alligator Bioscience; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibody

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alligator Bioscience
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Bispecific antibodies; Proteins
  • Mechanism of Action CD137 antigen agonists; Complement C5a inhibitors; Cytotoxic T-lymphocyte antigen 4 modulators; Immunomodulators; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors; OX40 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Preclinical Solid tumours
  • Research Cancer
  • No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Discontinued Reperfusion injury

Most Recent Events

  • 17 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer presented at the American Association of Cancer Research (AACR-2018) (9238191; 3318333)
  • 25 Jan 2018 Alligator Bioscience plans to submit CTA to regulatory authorities in Sweden and Denmark for the conduction of a phase I trial of ATOR 1015 in Cancer (Metastatic disease) by end of first half of 2018
  • 13 Sep 2017 Alligator Bioscience, Center for Applied Medical Research (CIMA) and Clinica Universidad de Navarra entered into research agreement to further investigate ATOR 1017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top